The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Safe and Effective Drug for Hepatitis C Genotype 4

Back to News Homepage

Next

Hepatitis C Vaccine in Production

FDA Grants Priority Review: Once-Daily, Single-Tablet Combination for HCV

August 3, 2015

Print this page

Find out about Merck’s chronic HCV treatment candidate grazoprevir/elbasvir.

Merck’s Hepatitis C Combination Candidate Receives Priority Review

ByKrystle Vermes

The FDA has granted priority review to Merck’s chronic hepatitis C virus (HCV) treatment candidate grazoprevir/elbasvir.

This once-daily, single-tablet combination was previously granted 2 breakthrough therapy designations for the treatment of chronic HCV genotype (GT) 4 infection, as well as chronic HCV GT1 infection in end-stage renal disease patients on hemodialysis. Now, the FDA is expected to act on grazoprevir/elbasvir 100 mg/50 mg for the treatment of adult patients infected with chronic HCV GT1, 4 or 6, on January 28, 2016.

Continue reading this entire article:
http://www.pharmacytimes.com/product-news/mercks-hepatitis-c-combination-candidate-receives-priority-review

No Comments - be the first!
Share
Share

Previous

Safe and Effective Drug for Hepatitis C Genotype 4

Back to News Homepage

Next

Hepatitis C Vaccine in Production

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.